Drugs / ADG20
ADG20
English name adintrevimab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04805671 | Jul 2021 → Feb 2022 | COVID-19 | Invivyd, Inc. | Terminated | Met primary |
| Phase 2/3 | NCT04859517 | Apr 2021 → Nov 2022 | COVID-19 | Invivyd, Inc. | Terminated | Met primary |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2022-03-30 | Invivyd, Inc. | Results Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization invivyd.com ↗ |
| 2022-01-12 | Invivyd, Inc. | Results Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron invivyd.com ↗
Findings across all three studies show that among mAbs in late-stage clinical development or with Emergency Use Authorization (EUA), ADG20 is one of only a few mAbs that demonstrated neutralizing activity against Omicron. |
| 2021-12-14 | Invivyd, Inc. | Results Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant invivyd.com ↗
The in vitro data generated through both authentic and pseudovirus testing of the Omicron variant show a greater than 300-fold reduction in neutralizing activity of ADG20 against Omicron. |
| 2021-11-29 | Invivyd, Inc. | Results Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro invivyd.com ↗ |
| 2021-11-15 | Invivyd, Inc. | Results Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results invivyd.com ↗
Data from a six-month evaluation in Adagio’s Phase 1 healthy volunteer trial of ADG20 confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg intramuscular dose that was given as a single injection. |
| 2021-10-19 | Invivyd, Inc. | Results Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants invivyd.com ↗
today announced new in vitro data demonstrating retained neutralizing activity of its monoclonal antibody (mAb), ADG20, against a diverse panel of circulating SARS-CoV-2 variants, including the newly emerged Lambda and Mu variants. |
| 2021-09-29 | Invivyd, Inc. | Results Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19 invivyd.com ↗
Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg IM dose that was given as a single injection. |
| 2021-05-05 | Invivyd, Inc. | Results Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19 invivyd.com ↗
Trial initiation is supported by positive preliminary data from the company’s ongoing Phase 1 trial in healthy volunteers. |
All press releases naming this drug 14 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADG20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04859517 ↗ |
| Modality | Monoclonal antibody | “adintrevimab, an extended half-life monoclonal antibody” PMID 37351456 ↗ May 2023 |
| Route | Intramuscular | “a single intramuscular injection of 300 mg adintrevimab or placebo” PMID 37351456 ↗ May 2023 |